The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys
Abstract
Objective: We tested the hypothesis that gene delivery of the trophic factor neurturin could preserve motor function and protect nigrostriatal circuitry in hemiparkinsonian monkeys. Methods: An adeno‐associated virus–based vector encoding human neurturin (AAV2‐NTN; also called CERE‐120) was injected into the striatum and substantia nigra of monkeys 4 days after a unilateral intracarotid injection of N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) rendered them hemiparkinsonian. Control hemiparkinsonian monkeys received either AAV2 encoding green fluorescent protein or formulation buffer. Results: Although stable deficits were seen in all control monkeys, AAV2‐NTN significantly improved MPTP‐induced motor impairments by 80 to 90% starting at approximately month 4 and lasting until the end of the experiment (month 10). AAV2‐NTN significantly preserved nigral neurons, significantly preserved striatal dopaminergic innervation, and activated phospho‐extracellular signal–regulated kinase, consistent with a mechanism involving a trophic factor–initiated molecular cascade. Histological analyses of numerous brain regions, including the cerebellum, showed normal cytoarchitecture and no aberrant pathology. Interpretation: These data demonstrate that AAV2‐NTN (CERE‐120) can preserve function and anatomy in degenerating nigrostriatal neurons and are supportive of ongoing clinical tests in Parkinson's disease patients. Ann Neurol 2006;60:706–715
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Neuropathology of Parkinsonʼs Disease
Forno, L. S. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,465
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251
Self-citationJing, S., Wen, D., Yu, Y., Holst, P. L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81311-2 · Cited by 1,174
Characterization of a multicomponent receptor for GDNF
Treanor, J. J. S., Goodman, L., de Sauvage, F., Stone, D. M., Poulsen, K. T., Beck, C. D., Gray, C., Armanini, M. P., Pollock, R. A., Hefti, F., et al. (1996) · Nature · doi:10.1038/382080a0 · Cited by 1,080
Perlmutter, J. S., & Mink, J. W. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112824 · Cited by 1,073
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Functional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 824
Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R., & Young, B. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 475
Viral gene therapy strategies: from basic science to clinical application
Young, L. S., Searle, P. F., Onion, D., & Mautner, V. (2006) · The Journal of Pathology · doi:10.1002/path.1896 · Cited by 313
Sanicola, M., Hession, C., Worley, D., Carmillo, P., Ehrenfels, C., Walus, L., Robinson, S., Jaworski, G., Wei, H., Tizard, R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6238 · Cited by 296
Long-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC
Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W., Reutter, B., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.005 · Cited by 282
Widenfalk, J., Nosrat, C., Tomac, A., Westphal, H., Hoffer, B., & Olson, L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08506.1997 · Cited by 251
Eslamboli, A., Georgievska, B., Ridley, R. M., Baker, H. F., Muzyczka, N., Burger, C., Mandel, R. J., Annett, L., & Kirik, D. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4421-04.2005 · Cited by 231
Crossroads in GDNF therapy for Parkinson's disease
Sherer, T. B., Fiske, B. K., Svendsen, C. N., Lang, A. E., & Langston, J. W. (2006) · Movement Disorders · doi:10.1002/mds.20861 · Cited by 172
Elsworth, J. D., Taylor, J. R., Sladek, J. R., Collier, T. J., Redmond, D. E., & Roth, R. H. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00437-6 · Cited by 115
Therapeutic Potential of Nerve Growth Factors in Parkinson??s Disease
Collier, T. J., & Sortwell, C. E. (1999) · Drugs & Aging · doi:10.2165/00002512-199914040-00003 · Cited by 94
Binding of GDNF and Neurturin to Human GDNF Family Receptor α 1 and 2
Cik, M., Masure, S., Lesage, A. S. J., der Linden, I. V., Gompel, P. V., Pangalos, M. N., Gordon, R. D., & Leysen, J. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000306200 · Cited by 74
Bézard, E., Gerlach, I., Moratalla, R., Gross, C. E., & Jork, R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.003 · Cited by 70
GDNF in treatment of Parkinson's disease: response to editorial
Penn, R. D., Dalvi, A., Slevin, J. T., Young, B. A., Gash, D. M., Gerhardt, G. A., & Hutchinson, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70360-x · Cited by 38
GDNF in treatment of Parkinson's disease: response to editorial
Lang, A. E., Langston, J. W., Stoessl, A. J., Brodsky, M., Brooks, D. J., DHAWAN, V. M., Elias, W. J., Lozano, A. M., Moro, E., Nutt, J. G., et al. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70359-3 · Cited by 33
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Missing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Self-citation
Metadata
- Authors
- Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-12
- Volume
- 60
- Issue
- 6
- Pages
- 706-715
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2117065100
- Cited by
- 252
- References
- 24
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.